Phase 3 Lymphoma Trial, Recruiting NCT06756152 Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology Condition: Lymphoma
Back to Lymphoma

Phase 3 Lymphoma Trial, Recruiting

NCT06756152
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People under the age of 21 years who have been diagnosed with one of the following conditions: acute lymphoblastic leukemia, myeloblastic leukemia, biphenotypic leukemia, bilinear leukemia, malignant lymphoma, or myelodysplastic syndrome.

Who may not be able to join:

  • People aged 21 years or older.
  • People with acute lymphoblastic leukemia (ALL) whose disease is not currently in remission (meaning the disease is still active in the blood and body).
  • People whose general physical ability and daily functioning scores below a certain level on standard medical rating scales (confirm with trial site).
  • People whose heart is not pumping efficiently enough — specifically, where the heart's pumping strength is measured at less than 40% on an ultrasound scan.
  • People whose kidneys are not filtering blood well enough, based on a standard kidney function measurement (confirm with trial site).
  • People whose liver is not functioning well enough, based on blood test results for liver enzymes and bilirubin being more than twice the normal range.
  • People whose lungs are not working well enough — either lung capacity is below 50%, or for children who cannot do a breathing test, blood oxygen levels are below 92%.
  • People with an active infection (viral, fungal, or bacterial) that is not under control.
  • People, or their caregivers, who have a mental illness that would make it difficult to understand the study or follow the required medical and hygiene instructions.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +79166512145

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Registry
ClinicalTrials.gov
Start date
10 July 2024
Est. completion
10 July 2026

Where this trial is recruiting

🇷🇺 Russia

Primary endpoints

1. Cumulative Incidence stage II-IV after HSCT; Kaplan Meier overal survival; 1. Cumulative Incidence stage II-IV after HSCT; Kaplan Meier event free survival; Kaplan Meier event free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov